Tularemia (Pneumonic)

Pneumonic tularemia is a rare but potentially life-threatening form of tularemia caused by Francisella tularensis, typically acquired through inhalation of contaminated aerosols or secondary to hematogenous spread.[1-2] This form has the highest mortality rate (up to 60% if untreated) and requires prompt recognition and treatment.[2]

The following figure illustrates the various transmission routes and clinical manifestations of tularemia:

View full figure Figure 1. Tularemia — Modes of Acquisition and Manifestations. Going Down the Rabbit Hole. N Engl J Med. July 31, 2024.

Key HPI questions

• • Onset and duration of symptoms (typically 3-5 days incubation, range 1-14 days)[4]
• • Fever pattern and severity (38.0-41.5°C)[4]
• • Respiratory symptoms: cough (often with scant sputum), chest pain, dyspnea[1][5]
• • Constitutional symptoms: fatigue, headache, myalgias, malaise[1][4]

Symptom characterization

• • Fever is typically high-grade and acute in onset[4]
• • Cough is usually nonproductive or with minimal sputum[6]
• • Chest pain may be pleuritic[5]

Timing, triggers, severity, progression

• • Symptoms develop 1-14 days after exposure (average 3-5 days)[4]
• • Can progress rapidly to severe pneumonia and respiratory failure[7]
• • May present initially as systemic illness without prominent respiratory signs[7]

Associated symptoms

• • Headache, myalgias, malaise, chills[4]
• • Abdominal pain, nausea, vomiting (especially in typhoidal form)[7]
• • Pharyngitis may be present[4]

Important negatives

• • Absence of skin ulcers or lymphadenopathy (distinguishes from ulceroglandular form)[7]
• • No conjunctival involvement[7]

Red flag symptoms/signs

• • High fever with rapid clinical deterioration[2]
• • Respiratory distress or failure[7]
• • Septic shock presentation[4]
• • Altered mental status[7]

Features suggesting life-threatening pathology

• • Pneumonic and typhoidal forms have highest mortality[2]
• • Rapid progression to severe pneumonia[7]
• • Signs of sepsis or multi-organ failure[7]

Indications for urgent escalation

• • Respiratory distress requiring oxygen support
• • Hemodynamic instability
• • Suspected bioterrorism exposure (requires immediate public health notification)[8]

Relevant medication contributors

• • Beta-lactam antibiotics are ineffective and should be avoided[9-10]
• • Anti-TNF agents increase risk of severe infection[6]
• • Immunosuppressive medications increase severity risk[6]

Common treatments

• • First-line for severe disease: Gentamicin 1.5 mg/kg IV q8h or streptomycin 15 mg/kg IM q12h[11]
• • First-line for mild-moderate disease: Ciprofloxacin 750 mg PO BID or levofloxacin 500 mg PO daily[8][11]
• • Alternative: Doxycycline 100 mg PO BID[11]

Contraindicated medications

• • Beta-lactam antibiotics (penicillins, cephalosporins)[9-10]
• • Most macrolides (except azithromycin in specific European strains)[10]

Medication interactions or cautions

• • Fluoroquinolones: avoid in pregnancy and young children due to musculoskeletal concerns[10]
• • Aminoglycosides: monitor renal function and hearing[11]

Dietary triggers or recommendations

• • No specific dietary restrictions during acute illness
• • Maintain adequate nutrition during prolonged illness

Hydration considerations

• • Ensure adequate hydration, especially with fever
• • Monitor fluid balance in severe cases

Important ROS questions

• • Respiratory: cough, dyspnea, chest pain, hemoptysis
• • Constitutional: fever, chills, night sweats, weight loss
• • GI: abdominal pain, nausea, vomiting, diarrhea
• • Neurologic: headache, altered mental status
• • Skin: rash, ulcers, lymphadenopathy

High-yield associated systems

• • Hepatic involvement (elevated transaminases common)[4]
• • Pleural involvement (effusions)[1][12]

Important collateral information

• • Recent outdoor activities in endemic areas[1][5]
• • Animal exposure (rabbits, rodents, cats)[13]
• • Tick bites or arthropod exposure[5]
• • Travel to rural areas[1][5]
• • Occupational exposure (veterinarians, hunters, laboratory workers)

Relevant hereditary conditions

• • Immunodeficiency syndromes
• • Family history of unusual infections

Social context

• • Rural residence or activities[1][5]
• • Hunting, trapping, or animal handling[13]
• • Laboratory work with potential F. tularensis exposure

Major epidemiologic risk factors

• • Rural residence or outdoor activities[1][5]
• • Contact with rabbits, rodents, or other small mammals[13]
• • Tick or deerfly bites[5]
• • Drinking untreated water[3]
• • Laboratory exposure[8]

Lifestyle contributors

• • Hunting, trapping, skinning animals[13]
• • Gardening, lawn mowing in endemic areas[3]
• • Camping in endemic areas

Comorbidities increasing risk

• • Immunosuppression (including anti-TNF therapy)[6]
• • Advanced age[12]
• • Chronic medical conditions[12]

Most important alternative diagnoses

• • Community-acquired pneumonia (bacterial, viral, atypical)
• • Tuberculosis[10]
• • Lung cancer or lymphoma[1]
• • Sarcoidosis[6]
• • Histoplasmosis or other endemic mycoses

Dangerous cannot-miss diagnoses

• • Pneumonic plague
• • Anthrax (inhalational)
• • Severe acute respiratory syndrome
• • Pneumonic tularemia in bioterrorism context[8]

Mimics and distinguishing features

• • vs. Tuberculosis: Tularemia has more acute onset, less cavitation[10]
• • vs. Lung cancer: Tularemia has fever, acute onset, exposure history[1]
• • vs. CAP: Tularemia often has mediastinal lymphadenopathy[1][12]

Relevant prior conditions

• • Previous tularemia infection (provides some immunity)
• • Immunocompromising conditions
• • Chronic lung disease

Previous episodes

• • Prior tick-borne illnesses
• • Previous pneumonias

Surgical history

• • Thoracic procedures
• • Immunosuppressive procedures

Chronic illnesses impacting management

• • Renal disease (affects antibiotic dosing)[11]
• • Liver disease
• • Heart failure

Key exam findings

• • Fever (often high-grade 38-41.5°C)[4]
• • Tachypnea, tachycardia
• • Pulmonary findings may be minimal early in disease[7]

Vital sign abnormalities

• • High fever[4]
• • Tachycardia, tachypnea
• • Hypotension in severe cases[7]

Focused exam maneuvers

• • Complete pulmonary examination
• • Lymph node examination (cervical, axillary, inguinal)
• • Skin examination for ulcers or rashes
• • Oropharyngeal examination

Expected vs concerning findings

• • Expected: Fever, mild respiratory findings initially[7]
• • Concerning: Respiratory distress, altered mental status, hypotension[7]

Recommended labs

• • Complete blood count (usually normal or slightly elevated WBC)[4]
• • Comprehensive metabolic panel
• • Liver function tests (often elevated transaminases)[4]
• • Blood cultures (low sensitivity ~10%)[6]
• • Respiratory cultures if productive sputum

Expected abnormalities

• • Normal or slightly elevated WBC with normal differential[4]
• • Elevated hepatic transaminases[4]
• • Elevated inflammatory markers (ESR, CRP)

Labs used to rule out dangerous conditions

• • Blood cultures to rule out other bacterial pneumonia
• • Sputum cultures and stains
• • Procalcitonin may be elevated

Monitoring parameters

• • Renal function (if using aminoglycosides)[11]
• • Liver function
• • Complete blood count

First-line imaging

• • Chest X-ray: may show patchy infiltrates, hilar lymphadenopathy, pleural effusion[4][7]

Gold standard imaging

• • Chest CT: consistently shows mediastinal lymphadenopathy and pulmonary nodules[1]
• • May show subpleural micronodules or pleural effusion[1]
• • Subpleural round consolidations are characteristic[12]

Important imaging findings

• • Mediastinal lymphadenopathy (very common)[1][12]
• • Pulmonary nodules or consolidations[1]
• • Pleural effusions[1][12]
• • May mimic malignancy on PET scan[1]

When imaging is unnecessary

• • Chest imaging is essential for suspected pneumonic tularemia

Diagnostic scoring systems

• • No specific scoring systems available

Point-of-care tests

• • None available

Procedures or specialty tests

• • Bronchoscopy with EBUS-TBNA may be performed[5]
• • CT-guided biopsy (shows necrotizing granulomatous inflammation)[1][5]

ECG findings

• • Generally not specific for tularemia
• • May show sinus tachycardia

Indications for ECG

• • Severe illness with hemodynamic compromise
• • Elderly patients or those with cardiac risk factors

Clinical summary

• • Pneumonic tularemia is a rare but serious form of tularemia with high mortality if untreated[2]
• • Often presents with nonspecific symptoms initially[1]
• • Imaging typically shows mediastinal lymphadenopathy and pulmonary nodules[1][12]

Severity stratification

• • Mild-moderate: Stable vital signs, minimal respiratory distress
• • Severe: Respiratory distress, hemodynamic instability, sepsis[2]

Typical vs atypical presentations

• • Typical: Acute febrile illness with respiratory symptoms and exposure history
• • Atypical: May present as systemic illness without prominent respiratory signs[7]

Complications to consider

• • Respiratory failure[7]
• • Septic shock[4]
• • Pleural effusion[1][12]
• • Treatment failure or relapse[9]

Initial stabilization

• • Supportive care for respiratory distress
• • Fluid resuscitation if hypotensive
• • Oxygen support as needed

Medications and dosing

• • Severe disease: Gentamicin 1.5 mg/kg IV q8h or streptomycin 15 mg/kg IM q12h[11]
• • Mild-moderate disease: Ciprofloxacin 750 mg PO BID or levofloxacin 500 mg PO daily[8][11]
• • Alternative: Doxycycline 100 mg PO BID[11]
• • Duration: 10-14 days for severe cases, 14-21 days for mild-moderate[9][11]

Outpatient vs inpatient treatment

• • Inpatient: Severe disease, respiratory distress, hemodynamic instability
• • Outpatient: Mild disease with reliable follow-up

Follow-up management

• • Monitor for treatment response
• • Watch for complications or relapse[9]

Admission criteria

• • Severe pneumonia or respiratory distress
• • Hemodynamic instability
• • Inability to tolerate oral medications
• • Concern for complications

Discharge criteria

• • Stable vital signs
• • Tolerating oral medications
• • Reliable follow-up available
• • No signs of complications

Observation indications

• • Borderline cases with mild respiratory symptoms
• • Elderly patients or those with comorbidities

Specialist consultation triggers

• • Infectious disease consultation for severe cases
• • Pulmonology if respiratory failure
• • ICU consultation for septic shock

Follow-up timing

• • 48-72 hours for outpatients to assess response
• • Weekly follow-up until resolution

Symptoms requiring immediate reassessment

• • Worsening respiratory distress
• • High fever despite treatment
• • Signs of sepsis or shock
• • Inability to tolerate medications

Patient counseling points

• • Complete full antibiotic course[9]
• • Expect gradual improvement over days to weeks
• • Avoid beta-lactam antibiotics[9-10]
• • Report worsening symptoms immediately

Expected recovery course

• • Fever typically resolves within 24-115 hours depending on severity[12]
• • Complete recovery may take weeks
• • Relapse rates 5-15% depending on antibiotic choice[10]

1. Pulmonary Tularemia: A Diagnosis Not to Overlook. — Zaghdoudi A, Robin F, Moulinie J, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2026.

2. Tularemia for Clinicians: An Up-to-Date Review on Epidemiology, Diagnosis, Prevention and Treatment. — Antonello RM, Giacomelli A, Riccardi N. European Journal of Internal Medicine. 2025.

3. Going Down the Rabbit Hole. — Burdick KJ, Ealick W, Vargas Acevedo H, Sectish TC, Sandora TJ. The New England Journal of Medicine. 2024.

4. Tick-Borne Diseases in the United States. — Spach DH, Liles WC, Campbell GL, et al. The New England Journal of Medicine. 1993.

5. Thoracic Manifestations of Tularaemia: A Case Series. — Vacca M, Wilhelms B, Zange S, et al. Infection. 2024.

6. Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis. — Schwarzová V, Schwarz J, Mitrová K, et al. Pediatric Pulmonology. 2023.

7. Tularemia as a Biological Weapon: Medical and Public Health Management. — Dennis DT, Inglesby TV, Henderson DA, et al. The Journal of the American Medical Association. 2001.

8. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, Winberg J, Mead PS. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2025.

9. Tularemia Treatment: Experimental and Clinical Data. — Maurin M, Pondérand L, Hennebique A, et al. Frontiers in Microbiology. 2023.

10. Tularaemia: Clinical Aspects in Europe. — Maurin M, Gyuranecz M. The Lancet. Infectious Diseases. 2016.

11. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.

12. Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones. — Widerström M, Mörtberg S, Magnusson M, Fjällström P, Johansson AF. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

13. Hunting for Tularaemia - A Review of Cases in North Carolina. — Rimawi RH, Shah KB, Chowdhary RA, Cook PP. Zoonoses and Public Health. 2015.